These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20883679)

  • 1. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
    Sander J; Janzen N; Terhardt M; Sander S; Gökcay G; Demirkol M; Ozer I; Peter M; Das AM
    Clin Chim Acta; 2011 Jan; 412(1-2):134-8. PubMed ID: 20883679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
    Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of NTBC in serum samples from patients with hereditary tyrosinemia type I by capillary electrophoresis.
    Cansever MS; Aktuğlu-Zeybek AC; Erim FB
    Talanta; 2010 Mar; 80(5):1846-8. PubMed ID: 20152421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients.
    Herebian D; Spiekerkötter U; Lamshöft M; Thimm E; Laryea M; Mayatepek E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(14-15):1453-9. PubMed ID: 19345648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
    Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.
    Thimm E; Herebian D; Assmann B; Klee D; Mayatepek E; Spiekerkoetter U
    Mol Genet Metab; 2011 Feb; 102(2):122-5. PubMed ID: 21112803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J; Wibrand F; Lund AM; Christensen M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory monitoring of patients with hereditary tyrosinemia type I.
    Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
    Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures.
    Prieto JA; Andrade F; Lage S; Aldámiz-Echevarría L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):671-6. PubMed ID: 21377430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Weed Killer to Wonder Drug.
    Lock EA
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
    Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
    J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN; Venugopalan P
    Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple and fast quantification of nitisone (NTBC) using liquid chromatography-tandem mass spectrometry method in plasma of tyrosinemia type 1 patients.
    Davit-Spraul A; Romdhane H; Poggi-Bach J
    J Chromatogr Sci; 2012 May; 50(5):446-9. PubMed ID: 22511487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
    Gissen P; Preece MA; Willshaw HA; McKiernan PJ
    J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
    Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
    Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma bile acid concentrations in two sisters with tyrosinaemia type I.
    Sass JO; Skladal D
    J Paediatr Child Health; 2000 Feb; 36(1):91-3. PubMed ID: 10723702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.